(Q37678723)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

L M Ortega

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

D R Schultz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

V Pardo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

G N Contreras

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

20 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

557-574

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20089610%20AND%20SRC:MED&resulttype=core&format=json

The classification of glomerulonephritis in systemic lupus erythematosus revisited

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Factors associated with poor outcomes in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

The prognosis and pathogenesis of severe lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Toll-like receptors in systemic autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Nucleic acid recognizing Toll-like receptors and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Mechanisms of immune-deposit formation and the mediation of immune renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Complement and coagulation: strangers or partners in crime?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Role of C5a in inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Complement deficiency and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Systemic lupus erythematosus, complement deficiency, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Novel packages of viral and self-antigens are generated during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Autoantibodies against C1q: view on clinical relevance and pathogenic role

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Autoreactivity to mouse C1q in a murine model of SLE

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

The cDNA sequence of a human placental alpha-actinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Expression of alpha-actinin-1 in human glomerular mesangial cells in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Mice deficient in alpha-actinin-4 have severe glomerular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Antineutrophil cytoplasmic antibodies (ANCA) and systemic vasculitis: update of assays, immunopathogenesis, controversies, and report of a novel de novo ANCA-associated vasculitis after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Demographic differences in the development of lupus nephritis: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Outcomes in African Americans and Hispanics with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Severe lupus nephritis: racial differences in presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Treatment of lupus nephritis: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Long-term treatment of lupus nephritis with cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Lowering anti-dsDNA antibodies--what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Antiphospholipid antibody syndrome and renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Factors affecting kidney-transplant outcome in recipients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

End-stage renal disease and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

Baseline characteristics of a multiethnic lupus cohort: PROFILE

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309358187